Avidity Biosciences, Inc. Board of Directors

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Ms. Sarah Boyce

Ms. Sarah Boyce

President, CEO & Director

Prof. Mark E. Davis Ph.D.

Prof. Mark E. Davis Ph.D.

Scientific Founder, Member of Scientific Advisory Board and Member of Board of Managers

Mr. John B. Moriarty Jr., ESQ., J.D.

Mr. John B. Moriarty Jr., ESQ., J.D.

Chief Legal Officer & Corporate Secretary

Mr. Eric B. Mosbrooker

Mr. Eric B. Mosbrooker

Chief Commercial Officer

Dr. Troy Edward Wilson J.D., Ph.D.

Dr. Troy Edward Wilson J.D., Ph.D.

Co-Founder & Independent Chairman

Mr. Michael F. MacLean CPA

Mr. Michael F. MacLean CPA

Chief Financial Officer

Ms. Teresa McCarthy

Ms. Teresa McCarthy

Chief Human Resources Officer

Mr. Charles Calderaro III

Mr. Charles Calderaro III

Chief Technical Officer

Dr. Frank P. McCormick Ph.D.

Dr. Frank P. McCormick Ph.D.

Scientific Founder & Member of Scientific Advisory Board

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.